1 results
Approved WMORecruiting
To evaluate whether Telisotuzumab Vedotin improves response rate and survival in participants who are c-Met+ with NSCLC. For the additional monotherapy cohort :Primary objective is to evaluate the safety and tolerability of telisotuzumab vedotin…